# BPC-157 (Capsule)

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/bpc-157-capsule (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: Oral BPC-157 for gastrointestinal healing, gut permeability, and systemic anti-inflammatory effects.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/bpc-157-capsule

\*\*Recovery & Repair · Moderate Evidence · Research Only\*\* ### BPC-157 Oral Capsule Oral BPC-157 for gastrointestinal healing, gut permeability, and systemic anti-inflammatory effects. ### Description Oral BPC-157 capsules deliver the gastric pentadecapeptide directly to the gastrointestinal tract, where it exerts potent local healing effects on the mucosal lining. BPC-157 was originally isolated from human gastric juice and has demonstrated remarkable cytoprotective properties across hundreds of preclinical studies. While injectable BPC-157 is preferred for musculoskeletal injuries due to higher systemic bioavailability, oral administration is particularly effective for GI conditions including leaky gut syndrome, inflammatory bowel disease, GERD, and gut dysbiosis. Research has shown that oral BPC-157 can accelerate healing of intestinal anastomoses, protect against NSAID-induced GI damage, and normalize gut motility disrupted by various insults. The oral route also allows for convenient once or twice daily dosing without the need for reconstitution or injection. ### Key Characteristics - \*\*Half-Life:\*\* Varies - \*\*Administration Routes:\*\* Oral capsule - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Once or twice daily ### Investigated Benefits - GI tract healing - Leaky gut repair - Reduced gut inflammation - GERD improvement - Systemic anti-inflammatory effects \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action “Oral BPC-157 for gastrointestinal healing, gut permeability, and systemic anti-inflammatory effects.” Oral BPC-157 acts locally on the GI mucosa by activating the FAK-paxillin pathway, which promotes cell migration and tissue repair at sites of mucosal injury. It stimulates angiogenesis through upregulation of VEGF and EGF receptors, improving blood supply to damaged intestinal tissue. BPC-157 also modulates the nitric oxide (NO) system, which plays a central role in GI mucosal protection and blood flow regulation. Anti-inflammatory effects are mediated through inhibition of NF-κB signaling and reduction of pro-inflammatory cytokines including TNF-α and IL-6. Some systemic absorption does occur, providing additional anti-inflammatory and healing effects beyond the GI tract, though at lower concentrations than injectable administration. ### Dosing Protocol - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Once or twice daily - \*\*Cycle Length:\*\* 4–12 weeks - \*\*Administration:\*\* Oral capsule \*\*Protocol Notes:\*\* Take on empty stomach for best absorption. For GI conditions, oral is preferred over injectable. Can be combined with injectable BPC-157 for comprehensive coverage. ### Storage Information Store at room temperature, away from light and moisture. Refrigerate for extended storage. ### Quality & Sourcing Standards When sourcing BPC-157 (Capsule) for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Oral administration shown effective for GI conditions in animal models 2. Phase II human trials for IBD with oral formulation 3. GI protective effects validated across multiple injury models ### Evidence Level \*\*Moderate Evidence\*\* Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited. ### Compatible Peptides Peptides commonly used alongside BPC-157 (Capsule) for synergistic effects. - \*\*Thymosin α1\*\* (Immune Support): The most clinically validated immunomodulatory peptide, approved in 35+ countries for hepatitis, sepsis, and immune deficiency. - \*\*BPC-157 + TB-500 (Capsule)\*\* (Blends & Combos): The Wolverine Stack in oral capsule form for convenient systemic recovery support. ### Quick Reference - \*\*Category:\*\* Recovery & Repair - \*\*Status:\*\* Research Only - \*\*Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Once or twice daily - \*\*Cycle:\*\* 4–12 weeks ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.